alanine has been researched along with Cytokine Release Syndrome in 15 studies
Alanine: A non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases IMMUNITY, and provides energy for muscle tissue, BRAIN, and the CENTRAL NERVOUS SYSTEM.
alanine : An alpha-amino acid that consists of propionic acid bearing an amino substituent at position 2.
Cytokine Release Syndrome: A severe immune reaction characterized by excessive release of CYTOKINES. Symptoms include DYSPNEA; FEVER; HEADACHE; HYPOTENSION; NAUSEA; RASH; TACHYCARDIA; HYPOXIA; HYPERFERRITINEMIA, and MULTIPLE ORGAN FAILURE. It is associated with viral infections, SEPSIS; AUTOIMMUNE DISEASES and a variety of factors used in IMMUNOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Ulipristal for uterine fibroids : market withdrawal due to risk of severe liver injury." | 5.12 | [Pharmacovigilance update]. ( Ekobena, P; Ivanyuk, A; Livio, F, 2021) |
| "BACKGROUNDSevere coronavirus disease 2019 (COVID-19) is associated with a dysregulated immune response, which can result in cytokine-release syndrome and acute respiratory distress syndrome (ARDS)." | 3.11 | Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome. ( Anderson, C; Neil, GA; Perlin, DS; Raines, S; Ware, CF; Wilkins, HJ; Zafir-Lavie, I, 2022) |
| "Favipiravir has resulted in a higher viral clearance than remdesivir." | 2.72 | A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic. ( Dehghan, H; Fazlzadeh, A; Haddad, F; Kheirabadi, D; Mousavi-Roknabadi, RS; Rezaeisadrabadi, M, 2021) |
| "Patients who experienced cytokine storms tend to have a high mortality rate." | 1.72 | Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination. ( Abu Bakar, U; Gan, SH; Jaber, AAS; Jusnita, N; Lukas, S; Pratiwy, I; Ramatillah, DL; Syed Sulaiman, SA, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 15 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vitiello, A | 1 |
| Ferrara, F | 1 |
| Perlin, DS | 1 |
| Neil, GA | 1 |
| Anderson, C | 1 |
| Zafir-Lavie, I | 1 |
| Raines, S | 1 |
| Ware, CF | 1 |
| Wilkins, HJ | 1 |
| Ramatillah, DL | 1 |
| Gan, SH | 1 |
| Pratiwy, I | 1 |
| Syed Sulaiman, SA | 1 |
| Jaber, AAS | 1 |
| Jusnita, N | 1 |
| Lukas, S | 1 |
| Abu Bakar, U | 1 |
| Drosos, AA | 1 |
| Pelechas, E | 1 |
| Voulgari, PV | 1 |
| Zhou, H | 1 |
| Fang, Y | 1 |
| Xu, T | 1 |
| Ni, WJ | 1 |
| Shen, AZ | 1 |
| Meng, XM | 1 |
| Nile, SH | 1 |
| Nile, A | 1 |
| Qiu, J | 1 |
| Li, L | 1 |
| Jia, X | 1 |
| Kai, G | 1 |
| Akinosoglou, K | 1 |
| Velissaris, D | 1 |
| Ziazias, D | 1 |
| Davoulos, C | 1 |
| Tousis, A | 1 |
| Tsiotsios, K | 1 |
| Kalogeropoulou, C | 1 |
| Spyridonidis, A | 1 |
| Marangos, M | 1 |
| Fligkou, F | 1 |
| Gogos, C | 1 |
| Magro, G | 1 |
| Manjaly Thomas, ZR | 1 |
| Leuppi-Taegtmeyer, A | 1 |
| Jamiolkowski, D | 1 |
| Steveling-Klein, E | 1 |
| Bellutti-Enders, F | 1 |
| Scherer Hofmeier, K | 1 |
| Hartmann, K | 1 |
| Shamim, S | 1 |
| Khan, M | 1 |
| Kharaba, ZJ | 1 |
| Ijaz, M | 1 |
| Murtaza, G | 1 |
| Gonzales-Zamora, JA | 1 |
| Quiroz, T | 1 |
| Vega, AD | 1 |
| Khiali, S | 1 |
| Rezagholizadeh, A | 1 |
| Entezari-Maleki, T | 1 |
| Ekobena, P | 1 |
| Ivanyuk, A | 1 |
| Livio, F | 1 |
| Kheirabadi, D | 1 |
| Haddad, F | 1 |
| Mousavi-Roknabadi, RS | 1 |
| Rezaeisadrabadi, M | 1 |
| Dehghan, H | 1 |
| Fazlzadeh, A | 1 |
| Ali, S | 1 |
| Khalid, S | 1 |
| Afridi, M | 1 |
| Akhtar, S | 1 |
| Khader, YS | 1 |
| Akhtar, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury[NCT04412057] | Phase 2 | 88 participants (Actual) | Interventional | 2020-07-17 | Completed | ||
| Inhaled Interferon α2b Treatment in Mild-to-moderate COVID-19 Infected Children[NCT05381363] | Phase 1/Phase 2 | 24 participants (Actual) | Interventional | 2022-01-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Respiratory failure defined based on resource utilization requiring at least one of the following:~Endotracheal intubation and mechanical ventilation~Oxygen delivered by high-flow nasal cannula (heated, humidified oxygen delivered via reinforced nasal cannula at flow rates >20L/min with fraction of delivered oxygen ≥0.5)~Noninvasive positive pressure ventilation,~Extracorporeal membrane oxygenation" (NCT04412057)
Timeframe: Baseline to Day 28
| Intervention | Participants (Count of Participants) |
|---|---|
| CERC-002 | 26 |
| Placebo | 20 |
1-month mortality defined as the number of subjects who are alive at the Day 28/ET visit (NCT04412057)
Timeframe: Baseline to Day 28
| Intervention | Participants (Count of Participants) |
|---|---|
| CERC-002 | 36 |
| Placebo | 36 |
9 reviews available for alanine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Treatment strategies of COVID-19: A rheumatology perspective.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Antibodies, Monoclonal; COVID-19 Drug Tre | 2022 |
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting En | 2020 |
COVID-19: Pathogenesis, cytokine storm and therapeutic potential of interferons.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal; Antiviral Agents; Betacoronavirus; Coronav | 2020 |
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Topics: Adenosine Monophosphate; Alanine; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Mono | 2020 |
Emerging treatments in COVID-19: Adverse drug reactions including drug hypersensitivities.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized | 2020 |
Potential strategies for combating COVID-19.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Alanine; Amides; Antibodies, Monoclonal, Humanized | 2020 |
A comprehensive review on sarilumab in COVID-19.
Topics: Adenosine Monophosphate; Alanine; Animals; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVI | 2021 |
[Pharmacovigilance update].
Topics: Adenosine Monophosphate; Alanine; Cleft Lip; Contraindications, Drug; COVID-19 Drug Treatment; Cytok | 2021 |
A complementary critical appraisal on systematic reviews regarding the most efficient therapeutic strategies for the current COVID-19 (SARS-CoV-2) pandemic.
Topics: Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Chloroquine; COVID-19; COVID-19 Drug Tre | 2021 |
1 trial available for alanine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.
Topics: Adenosine Monophosphate; Adrenal Cortex Hormones; Adult; Alanine; Antibodies, Monoclonal; COVID-19; | 2022 |
5 other studies available for alanine and Cytokine Release Syndrome
| Article | Year |
|---|---|
Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection.
Topics: Adenosine Monophosphate; Adult; Alanine; Antiviral Agents; Azetidines; COVID-19 Drug Treatment; Cyto | 2022 |
Impact of cytokine storm on severity of COVID-19 disease in a private hospital in West Jakarta prior to vaccination.
Topics: Adenosine Monophosphate; Adult; Aged; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humani | 2022 |
Remdesivir and tocilizumab: Mix or match.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; COVID-19 Drug Treatment; Cytoki | 2021 |
Successful treatment with Remdesivir and corticosteroids in a patient with COVID-19-associated pneumonia: A case report.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-1 | 2020 |
Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
Topics: Adenosine Monophosphate; Aged; Alanine; Antibodies, Monoclonal, Humanized; Antiviral Agents; COVID-1 | 2021 |